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INTRODUCTION.
Thyrotoxicosis is a disease of unknown etiology
in whioh the pituitary gland stimulates the thyroid in such
manner that the cells of the thyroid become hyperplastic
and hypertrophio, the gland enlarf's, the colloid stores of
the thyroid become depleted, the amount of thyroid hormone
circulating in the blood stream inoreases, and as a result,
a hypermetabolic state develops.

These changes affeot the

functions of all of the tissues in the body, producing a
group of classical manifestations; the most outstanding of
which are nervousness, palpitation, hyperpyrexia, weight loss,
hea� intolerance, excessive sweating, exophthalmos, weakness
and tremulousness.
This thesis will attempt to evaluate medical
treatment of thyrotoxicosis in general.

Medical treatment

consists of the application of a broad regime of therapy
embracing an individually calculated rest program in associa
tion with dietatio, hygienic, medicinal, psychotherapeutic,
and other measures based on the view held by competent ob
servers that Grave's syndrome is due to. a widespread dys
function of the endocrin glands and of the autonomic nervous
system. (13).
In the evaluation of this form of therapy numerous
difficulties arise.

It is easy enough to evaluate and compare

such tangible factors as the basal metabolic rate, the pulse
rate, and the return of body weight.

However, there are

certain intangible factors in thyrotoxicosis that are not
measurable.

We have no measure · of tempermental changes; of

feeling of well being or the re:verse; of psychic stability;
and except in a crude way of general physical strength or

•

capacity to work.

These are the factors that the competent

clinician "sizes up", but these are very difficult to report.
Other complicating factors in these reports are the notorious
variability of remissions and exacerbations, the confusing
factors such as rest and sedation, and the la.ck and difficulty
of getting satisfactory follow-ups •
The therapeutic approach to any disease entity in
order to be fundamentally successful must attack the primary
pathologic physiology.

In thyrotoxicosis, where the primary

pathologic physiology is unknown, the regime of therapy must
be aimed to produce symptomatic relief by establishing equilibrium of the involuntary mechanism of the body through
measures direc.ted toward endocrine and mental adjustment.
Moreover, recovery must be made conclusive by efforts at
increasing the zone of defense against relapse.
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THE GENERAL THERAPEUTIC APPROACH.

The physician must meet the patient on the common
grounds of understanding, and one of the first techniques
that must be utilized in the treatment of thyrotoxicosis is
psychotherapy .

Psychic trauma is a definite factor in the

progression of the disease.

The removal of the patient from

the cares of daily life or freeing him from oppressive
psychic conflicts often causes marked improvement.

In deal-

ing with patients presenting exophthalmic goiter, one must
always bear in mind their extremely sensitive, high strung,
and complex natures.
be eliminated.

All sources of worry and anxiety must

If the economic status of the patient permits,

a vacation under complete change of environs and complete
freedom from responsibility may be of untold benefit.

The

fruit of properly applied psychotherapy is cooperation without which recovery is impossible.

Psythotherapy in thyro-

toxicosis results in an increase in the threshold of emotional
reaction, the first step in substitution of reason for panic .
1he patient is made to realize that emotionalism and reasonin.,,g cannot occupy the mind at the same time; that in event
of impending mental excitement the remedy i s analysis of the
situation.

T~is analysis becomes habitual and serves to

avoid excitability and replace it with a sense of calm.
3

Though psychotherapy alone cannot cure Grave's disease, the
process of mental adjustment is the foundation upon which the
efficacy of other measures depends.
Means and Aub (116) noted that a large percent of
cases, whether mi ld or severe, show a marked fall in the
basal metabolic rate on rest alone.

This fall occurs over

a

-

period of from one to three weeks, and then a plateau is
reached.

Th is fall in basal rate on rest alone gives rise

to confusion in t he interpretation of other therapeutic
mea.sures.

In severe thyrotoxicos is activity should be re-

duced to a minimum, because any activity raises the metabolic
rate.

Minnig (123) gauges the amount of rest necessary by

the amount of damage to the heart and central nervous system;
he estimates this by heart rate, basal metabolic rate, vital
capacity, etc.

Physical rest shares with mental reassurance

the task of conservation of calories.
When a patient has a basal metabolic rate of plus
100, it must be remembered that caloric needs a r e 100% more.
There is an increased breakdown of tissues, both essential
and those in food stores, and unless a conce ntrated high
caloric diet is given, the patient cannot eat such bulk.
The diet should be high in carbohydrate to replace de pleted
glycogen stores and relatively high in protein for the total
serum protein is low in thyrotoxicosis.
4

The food most valuable

in building up the tissues that have been oatabolized is
protein, but care must be taken due to the high specific
dynamic action of protein which tends to increase the metabolic rate.

To maintain appetite and enhance carbohydrate

metabolism, adequate B complex vitamins should be given;
especially thiamin.
The amount of food required by the patient is
dependent upon these variables:
1.

The amount of food ordinarily required by the
patient during good health.

2.

The amount necessary to combat the results of the
hypermetabolism.

3.

The amount required to regain lost weight .

4.

The additional quantity necessary to effect a 5
to 10 percent increase over and above the patient's
normal standard of wei ght to be retained as a buffer.
( 13).

In thyrotoxicosis there may be a more or less marked avitaminosis Tesulting from increased consumption to some
extent proportional to the basal metabolic rate, or from decreased absorption due to disturbance in the function of the
gastrointestinal tract.
A and

c.

This applies espec i ally to vitamins

Long standing thyrotoxicosis is also nearly always

associated with a Vitamin B deficiency and cardiac abnorrnali5

ties may themselves be on this basis.

Vitamin B deficiency

in man results in tachycardia, palpitation, dyspnea, fatiguability, etc.

Certainly no more characteristic list of the

major cardiovascular symptoms of early or moderate hyperthyroidism could be compiled.

In the early phases of hyperthyroidism

there is an increase in appetite, but in later phases there
may be a ·failure and during this period the weight loss may
be greater.

During this state the appetite declines, gastro-

intestinal atony is observed and intestinal absorption dimishes.
Therefore, a B deficiency is a matter of no mean importance
in the treatment of toxic thyroids •

.An adequate dosage is

700 to 900 IU daily. {144).
There is an incre ased excretion of calcium in
thyrotoxioosis through both the gastrointestinal and urinary
tracts.

However, the blood calcium and phosphorus usually

remain within normal limits; the difference is made up from
the natural calcium stores in the body such as the bones.
The disturbance in calcium metabolism in hyperthyroidism
varies greatly.
reversible.

It is usually temporary, preventable , and

It can be easily controlled by ingestion or

parenteral administration of extra calcium.

This can be

given in milk, calcium gluconate, calcium lactate with vitamin Dor calcium chloride intravenously.

In long standing

oases, however, certain changes take place in bones which
6

are not ameliorable .

A great improvement is noted in the
I

musoulo-skeletal symptomatology when 1800 to 3160 milligrruns
of calcium is given . (143).
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ENDOCRINE THERAPY.

That a relationship exists between the ovaries and
the thyroid has long been recognized, but the exact relationship is still obscure.

Since the anterior l obe of the pitui-

tary is the stimulating factor for both of these glands it
is possible that variations in one can extend to the other.
It is often observed that at the onset of puberty, during
pregnancy, and lactation, and at the menopause there is often
an increase in size.

In hyperthyroidism irre gular menses,

menorrhagia, and amenorrhea are seen; t h is may be due to a
specific or non-specific act i on on the gonadal cells.
The results and interpretations of experimental
data, clinical observations, and investi gations on t his

sub-

ject are, for the most part, contradictory, uncertain and
scanty.

The number of cases treated are few, the dosages

and durations of treatment are di f ferent, with consequent
wide variation in result s.
Hitchcock and Wardwell (74) studied the cyclic
Tariations of the basal metabolic rate in women and observed
t hat two-thirds of them have a decreased basal rate during
the menstrual period following a premenstrual rise and a low
point at the time of ovulation.

They sugge st an inverse

relation with the ovarian hormone in the blood for its rises
8

and falls are inversely correlated with the basal metabolic
rate.

.

At least there is general agreement on one point, hyper-

thyroidism is often associated with marked ovarian changes.
The mode of action is obscure, but in Starr and
Patton's series of cases, (167, 168) they observed that in
patients with normal ovaries the thyrotoxicosis was benefitted
by estrogenic therapy, but in patients with failing ovarian
function the results were very discouraging.

They believed

that the pregnancy urine extract stimulated production of
estrin which inhibited the thyroid.

The mechanism may be

depression of gonadotropio hormone secret ion ( 60), or by a
direct depressant action on the tissues (60, 159).

All of

t his is purely speculative and nothing has been demonstrated
conclusively.
Starr (166) treated a series of 13 patients with
either Antuitrin Sor Theelin and 7 responded with no recurrence in 18 months.

These had ttnormal" ovarian functd.on.

They showed decreased basal metabolic rate, decreased symptomatology, and increase in weight.

Shute and Shute (160)

noted decrease in heart rate and increase in weight, after
estrogen therapy, but no decrease in basal rate, exophthalmos,
size of the gland, tremor, or perspiration.

Farbman (43)

with 9 cases showed that massive doses of estrone do not
directly decrease the basal metabolic rate nor change the
9

disease in severe or moderate cases but in mild cases there
is rapid and lasting response of all symptomatology.

It

has been observed that if the therapy is going to do any
good, the basal metabolic rate and symptoms clear at once. (60).
Storck and Sabatier (171) used estrogens and Stilbesterol

.

post-operatively with good results and no crises.
lfiide variations in dosage, method, and substance
used have been reported.

Starr and Patton (167, 168) used

1 cubic centimeter of Antuitrin S (100 RU) or of Theelin
(50 RU) given subcutaneously, daily or three times a week
for specified periods before or after menses for 4 to 5
months "as indicated".

Goldman, et al, (60) used Progynon B

(estrogenic hormone) 50,000 units each day until a total
dosage of 500,000 to 750,000 units had been given.

Storck

and Sabatier (171) used 2000 units of Theelin given intramuscularly in oil each day, and or, Diethylstilbesterol
orally.

They used a wide variation in dos age, but the small

doses seemed as effective as the large doses •
Th is discussion would seem to indicate that therapy
with estrogens was indicated ohly in patients with thyrotoxicosis who have "normal" ovarian function.

However~ the

number of cases reported is far too small to be statistically
important in attempting to draw any conclusions.
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In thyrotoxicosis, there is an increased urinary
nitrogen and hypercreatinuria .

This would seem to indicate

an excessive protein catabolism leading to a loss of weight.
Testosterone . propionate has just the opposite effect; i.e.,
protein anabolic and creatine retaining .

The protein loss

and decreased weight are connected with increased energy output.

Testosterone causes a marked nitrogen retention; i.e.

a synthesis of protoplasm rathe r t han tearing down.

Th is is

demonstrated by a .retention of the other constituents of
protoplasm in the same ratios as in protoplasm.

Since thyro-

toxicosis is characterized by an increase in the uri nary excretion of nitrogen and creatine and by a loss of weight, and
since testosterone has the opposite e ffect on these three
variables, it is logical that it would do much to control
them.

It definitely improved the clinical status of the

patients, but produced no change in the basal metabolic r.ate.
However, it may prove a useful adj?vant in preparing patients
for operation who have suffered a marked weight loss.

A daily

dosage of 12 .5 milligrams is probably adequate, but this should
be in addition to the primary therapy to reduce the basal rate.
( 84).
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IODINE THERAPY.

Iodine has been the unknown active principle in
therapeutic concoctions which have been used for centuries
in the treatment of goiter.

The first authentic record was

found in Praotica written about 1170 by Roger of the University of Salerno.

Roger described goiter and prescribed

ashes of sponge and sea weed.
In 1820 1 Coindet 1 a Swiss doctor, first demonstrated that it was iodine that benefitted goiter .

Chatin, a

French physician 1 in 1850 demonstrated that small doses of
iodine would prevent endemic goiter and cretinism.

Follow-

ing the reports of Coindet, Chatin, et al, the use of iodine,
usually as Potassium iodide, in the treatment of an affliction of the thyroid became very oommon 1 and as a result 1 it
was found that many patients, rather than being benefitted,
were made worse.
When numerous authors, especially T. Kocher,
observed that some forms of goiter were precipitated into
thyrotoxicosis when treated with iodine, a fact that had
been known since Coindet's time, iodine was rejected in the
treatment of hyperthyroidism. (53).
Marine, as early as 1911 (101) found iodine to be
efficacious in the treatment of thyrotoxicosis, and ten years
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later E. Neisser, Loewy, antl H. Zon~ek supported belief in
the favorable effect of iodine administration on the clinical

.

course of the disease and on the basal metabolic rate.
However, systematic iodine therapy remained to be introduced
by Plummer in 1923. (139).
This short history demonstrates clearly the cyclic
response of the medical profession to any new form of therapy;
the initial use with success, then its use for any condition
related to the pathology treated successfully, increasing
numbers of failures and reports of toxicity with consequent
swing to the other extreme of the cycle.

Later, after trial

and error, a gradual acceptance of the therapy with its limitations.
Cohn (23) in a series of experiments noted that,
though a considerable amount of iodine is abso r bed by the
stomach, the majority is absorbed in the small and large
intestine.

The iodine is absorbed almost equally by the

small and large intestine, the only difference being that
the power of absorption from the large intestine is somewhat
less.

For instance, in experiments conduct ed with isolated

segments, the small intestine may absorb about 80% and the
large intestine about 62%.

He also states t hat t he power of

absorption did not vary with the chemical nature of the iodine
containing compounds.
13

It was demonstrated by Cohn (23), and Lennan and
Means (90) that free iodine is converted into iodides before
it is absorbed.

This refutes the assumption that free iodine

is more efficacious in the treatment as was originally stated
by ~lummer. (139).
After oral administration of iodides, Cohn proyed
that BO% was gone from the small intestine in two hours.
However, the functional condition of the gastrointestinal
traot must be taken into oonsideration.

During a period of

disturbance in the alimentary canal, the absorption of iodine
is somewhat deficient and the curve in the b lood level may be
lower and its rise slightly delayed.
Owing to the gr-eat ease with which iodides are
absorbed from the gastrointestinal tract, the iodine appears
very rapidly in the blood and the highest curve is obtained
in 30 to 60 minutes.

The height and durat i on of the curve

is dependent upon the dosage . (41).
Elmer (41) states that the rapid disappearance of
the iodine from the blood is chiefly dependent upon excretion
by the kidneys.

Usually the most pronounced elimination of

iodine given in small doses is found durin~ the first 24 hours,
while in the following days, it is less.

Iodine elimination

during the first 6 hours is the greatest in amount and the
most stable, whereas, during the rest of the day it decreases

14

considerably.

In the first few hours after the administration

of iodine, the urinary iodine elimination most frequently lies
between the limits of 13 to 17% of administered drug a.nd during the whole day it lies between 21 and 32%.
Cole and Curtis (25) estimate that approximately
So% of the total iodine, both of exogenous and endogenous
ori gin is excreted by the kidney.

They state that the a.mount

of iodine excreted in the faeces in mah lies within variable
limits.

It is in amount the sma l lest of the excretory iodine

fractions.

They state that between 6 and 27% of iodine is

excreted in the faeces.

This remarkable inconstancy is due

to the variance in the funct·ion of the gastrointestinal tract.
The faecal iodine is almost all of exogenous origin.

They

also observe that the skin plays a. role seoond only to the
kidney in excretion of iodine, but that it varies with the
amount of perspiration.
Iodine exists in the thyroid in different combinations, the larger amount in organic form, and only a. small
portion in inorganic form.

Seidell and Fenger (158) observed

that the iodine content of the human gland is definitely not
constant.

It varies with many factors, both physiological

and unphysiological.

Diet plays an important part; there

being a marked increase when the subject is on an iodine
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rich diet.

This is due to the marked affinity of the gland

for iodine.

There are definite seasonal swings, ·the content

being least in the winter.
the content.

Age has a definite effect upon

The amount of iodine in the thyroid increases

systematically from birth to puberty.

It reaches its maximum

at about 20 years and then remains stationary until the age
of 50 after which it steadily declines.
Marine and Feiss (104) observed that the power of
storing iodine was specific to the thyroid; other organs,
such as the spleen, liver, kidneys, and muscles do not possess
this power to an~~hing like the same degree.
It was noted by Marine and Rogoff (106) that iodine
accumulated in the thyroid was retained much longer than in
other organs.

The thyroid abstracts and retains the iodine

remarkably, its storage occurring immediately after its
introduction resulting in a lower concentration of iodine in
the vein than in the artery.

Iodine administered in small

amounts is probably quickly transformed into diiodotyrosine
and later into thyroxine.

The storage of inorganic iodine

occurs in the t hyroid only after the administration of greater
amounts of iodine.
Fraser (46) observed that after iodine had been
given and then the administration stopped, the iodine that
was stored in the gland was retained for a length of time
16

that seemed inversely pro portional to the severity of the
toxicity or hyperfunction.

As a consequence, a second course

of iodine is disappointing unless sufficient time has elapsed .
Subsequent to iodinization, there is a sharp increase in hyperiodemia.

Coupled with t he subside nce of clini-

cal symptomatology t his seems a lmost paradox i cal.

However,

Curtis ( 32) states that t his increase is ch iefly due to the
I

inor gan ic fraction and is due to the medication, wh ile there
is a definite decrease in the alchol soluble, or or ganic fraction .

There is no co nstant correlation between b lood iodine

and basal metabolic rate, except that the y are both i ncreased
in thyrotoxicosis.
The nature of the action of iodine in thyrotoxicosis
still remains obscure .

The question first arises by what path

t he iodine action is brought about.

Does the iodine aot

directly upon the thyroid gland, primarily in the tissues at
t he periphery, or on other endocrine organs such as the anterior pituitary?
The obs ervations of Carson and Dock (19) seem to
speak a gainst t h e action of iodine at the periphery .

Th~ o-

toxicosis provoked in man by the administrat ion of thyroxine
cannot be impr ove d by io dine a dministration, wh ile the thyrotoxic cond i ti on due to s pontaneous hyperfunotion of the thyroid,
or to thyrotropic injections is ameliorated.

17

It has also been demonstrated by Siebert and
Thurston (157) that the basal metabolic rate shows a gradual,
st~ady and considerable rise in guinea pigs after either
thyroid feeding or thyrotropic hormone injections, but when
iodine is given at the sane time as the thyrotropic hormone
is injected, the metabolism fails to show any marked rise.
In view of these differences, it is probable that iodine
acts in the main not at the periphery, " in the tissues, but
through the thyroid.
It may be that a part of the iodine action of the
thyroid gland is brought about indirectly through the effect
of the anterior pituitary, by checking production and excretion of the thyrotropic hormone.

However, Chapman (20) ob-

served that the thyroid is able to respond to the stimulus
of low iodine even in the absence of the pituitary.

The re-

sponse is the same in intact animals and those without a
pituitary gland.
Plunnner (138) postulated the theory of the manufacture of an abnormal thyroxin in untreated exophthalmic
goiter; abnormal in having an insufficient amount of iodine
and an increase in toxicity due to an increase in catabolic
action.

The supply of excess iodine substitutes the normal

for the abnormal.
' Marine (103) suggests that iodine has a purely
mechanical action dependent upon the rapid formation of
18

colloid which mechanically blocks deli very of thyroxin.
Morton, Chaikoff, and Rosenfeld (126) questioned
whether the inhibition might not be due to iodination of an
enzyme or enzymes concerned with the conversion of inorganic
iodide to thyroxine and diiodotyrosine.

If this were true

inorganic iodine would seem to serve not only as the precursor
of thyroxine and diiodotyro$ine, but also as an agent regulating the concentration of the enzyme in the thyroid tissue concerned with their formation.

In their experiments it was de-

finitely proven that inorganio iodine inhibited the formation
of thyroxin and diiodotyrosine at the expense of the inorganic
iodide of the mediutn.
From this brief summary it is obvious that this
field of investigation is still in a state of flux and that
no defini~e conclusion can be reached until further experimentation has been carried out.
Reinhoff (147) examined the histological changes
in the thyroid after therapy with Lugol's solution and observed that the clinical improvement and lmvered basal metabolic rate were directly associated with a change from the
typical histological picture of exophthalmic goiter to a resting colloid state.

He concluded that this artificial re-

mission was due to iodine.

He states that iodine increases

the size of the gland and makes it firmer; the capsule

19

thickens and lobulation becomes more pronounced, and there
is decreasing vascularity.

There is an increase in fibrous

connective tissue and an increase in colloid that distends
the acini.

The acini are regular in size and form, howe'Ve r,

The blood vessels are less prominent and the cells are less
'Variable in size and shape.

The acini are lined with low

cuboidal epithelium instead of high columnar.
The pre-iodine picture s ho'Y/S a gland with dilated
blood vessels, i ncreased parenchyma, and decreased colloid.
There are irregular lace-like acini, and the colloid is sc ant
and poorly staining .

The epithelium is hi gh columnar and the

walls of the acini are folded in upon themselves in papil~omatous growths. (147).
Goetsch (69) noted that the gland, after treatment
with iodine, becomes firm and hard due to t he rapid accumulation of colloid in the acini.

The vasc ular i ty decreases and

as a consequence, the thrills and bruits commonly found over

the superior pole decrease.

He cautions against excessive

medication that might make the gland friable and adherent to
the trachea.
An exhaustive study was made on cases of thyrotoxicosis treated at t he Mayo Clinic • by Weir. ( 186).

He

observed in 87.9% of oases with thyrotoxicosis that an involutional change in the histolo gical picture of the thyroid
20

was found when treated with iodine.

The clinical improvement

was accompanied by an iodine increase in all glands treated.

The iodine increase is to a certain extent directly proportional to the involutional changes in the histological picture of
the thyroid.

As a direct converse of that, Marine and Lenhart

(105) observed that in the thyroid the iodine content varies
inversely with the amount of hyperplasia present .

Weir states

that this marked increase of the iodine concentration is in
the main due to an increase in the organically bound iodine
and not due to inorganic iodine .
Marine and Lenhart also observed that the average
i9dine concentration in thyrotoxic glands amounted to 1.14
Mgm

%in

dessicated thyroid untreated with iodine; this rises

after iodine therapy on the average to 3.08 Mgm

%per

gram

of thyroid.
Cole (24) describes a typical response to therapy
with iodine.

He states that during the first few weeks the

subjective symptoms of palpitation, nervousness, heat and
gastrointestinal discomfort were greatly decreased .

The

heart rate dropped, the tremor decreased and patients were
calmer and more composed.

The maximum improvement ca..~e at

variable times, but usually between 10 days and 6 weeks with
continuous treatment.

Most patients showed a steady gain

in weight after the first week, but the basal metabolic rate
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was slower to respond and had its lowest point in an average
of 2 to 3 weeks.

When the treatment was continued past this

point of maximum efficiency, the basal rate rose again in
most cases, but in others remained stationary in an improved
condition.

In those in which the basal rate rose once more,

the former toxicity was not reached as long as the iodine
was taken;
Iodine does not modify the course of the disease,
but merely produces a moderation in the severity of the symptomatology.

If available in sufficient amounts, it enables

the disease to run its course at a lower le~el of severity.
Fraser (46) observed that the i mprovement obtained with iodine
therapy varies according to the state of the thyroid gland
and the amount of available iodine it contains.

The diffuse-

ly hyperplastic gland which contains little iodine will react
markedly to iodine, but when the gland already contains much
iodine and the extent of the hyperplasia is less, the symptomatic response will be less.

When iodine has been given

and the administration ceased, the iodine that was stored in
the gland is retained for a length of time that seems inversely proportional to the severity of the toxicity or hyperfunction.
Means, Thompson, and Thompson (118) state that the
de clivity of the curve of the basal metabolic rate is directly
related to its initial height; the greater the latter, the
22
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steeper the former.

Vfuen the iodine is continued beyond its

maximum effect, the basal rate usually rises slowly.

However ,

when the iodine is omitted, the basal metabolic rate usually
rises abruptly indicating that the natural course of the disease is not changed.

They also state that the speed of the

drop in the basal metabolic rate is not affected by the size
of the dose so long as it is sufficient to give the maximum
effect.

The average time for the maximum effect is 7 days,

with an average drop in basal metabolic rate of 4.4 points
each day.

Once a drop in the basal rate starts it drops

rapidly until it stops at its maximum effect.
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Means and Lerman (117) believe that refractoriness
to iodine therapy is apparent rather than real, for if a
patient is getting worse after continuous therapy, he should
not get worse when iodine is removed.
worse.

However , he gets much

So, if the patient begins to get iodine

11

fast 11 you

have a choice of continuance of therapy or of discontinuance
for a time and then reinstitution of the therapy.

They feel

that the logical course is to continue the therapy following
a policy of watchful waiting .

They assume that the patient

becomes ttfast 11 merely due to therapy on the upswing of the
cyclic course of thyrotoxicosis.

Means (112) observed that

even though the basal metabolic rate stayed up, the heart
rate dropped and the weight increased.
improvement in 81% .

There was subjective

He states that these patients also have

a mild post-operative phase and a low operative mortality .
However, if these statements are true, why aren't there more
patients who are "fast", for what patient seeks treatment
when he is improving.

There are also very few \tfast'' patients

among those not treated before.
Mayo (110) states that Lugol's solution was used
freely in all patients who had toxic adenom.as, and no harm
was ever seen from its use.

However , the results are very

varied and the benefits are far lass constant and pronounced
than in exophthalmic goiter.
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Lerman (89) in a review of 731 oases treated with
iodine showed that 96.6% showed a favorable reaction to the
drug by a decrease in basal metabolic rate.

Only 3.4% showed

no response.
Shortly after Dr. Plummer reintroduoed the use of
iodine for hyperthyroidism he stated that iod ine was a boon
to patients with diffusely toxic goiter, but that i't was useless in toxic nodular goiter.
and Culter.

This was disproven by Means

They demonstrated that iodine was useful in the

pre-operative preparation of both types of hyperthyroidism
and that it causes essentially the same involution.
The effect of iodine upon hyperthyroidism is dramat-

ic not merely because of its striking depressant activity on
the clinical manifestations of the disease, but also on account of the temporary duration of its beneficial influenoe.
Friedgood states that studies on the thyroid gland under
diverse experimental and clinical conditions have revealed
that its behavior is consistently influenced by a factor
which limits its ability to respond indefinitely to any
stimulus tending to disturb its functional capacity.

It is

obvious therefore, that the period during which the thyroid
can be maintained in an abnormal physiologic state i~ consistently limited.

Excitant and depressant stimuli cause a

departure of the gland from its normal functional state in
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a direction governed by the nature of the stimulus.

After a

certain period, in which the maximum change has been affected,
a spontaneous remission occurs.

The return to the original

level progresses in spite of, or because of, the continued
presence of the stimulus.
In a survey of the goiter management at the University of Nebraska Hospital, Davis presents the following chart
to demonstrate reaction of hyperthyroid patients to therapy
with Lugol's solution.

The cases are classified as severe -

B.M .R. plus 60 or above, mode rate - plus 20 to 60, and borderline - nor mal to plus 20; they are also classified as diffusely toxic and toxic nodular. (36).

TOXIC DIFFUSE GOITER
TOXIC NODULAR GOITER
Severe
Mod .
Border- Severe Mod. Border
line
line
Average
Basal Rate
at Entry

1+70

I +40.1 I +11

Average
Basal Rate
at Operation

1+42.8

1+2s .8 I + 6.3 I

I +12.s 1 +36.1 1 +12.6

+so.4

I +21.s I + 9.8

This demonstrates clearly the limitations of iodine
therapy incdecreasing metabolic rate.

It also shows that the

results of therapy in toxic nodular goiter are not so consistent,
nor so marked as with diffuse hyperplasia.
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The specific response to iodine therapy will occur
at any time in the course of the disease.

However, it does

not alter the duration or direction of the progress, - but
merely holds in abeyance a portion of the symptoms.

The

great majority of patients respond favorably to a regime of
iodine therapy, but there are definite limitations to the
length of time a favorable response can be maintained.

The

prognosis of patients who formerly developed the crises of
exophthalmio goiter is no longer hopeless and even patients
with extreme activation, dirrhea, vomiting, fever, delirium
and coma can now usually be controlled by iodine therapy.
Every doctor shows some variation in his regime
of iodine therapy, but the differences in dosage seen now
make relatively little difference as long as they are above
the minimal effective dose.

Formerly enormous doses were

given; up to 400 times the minimal requirement, but no greater
effect was obtained.
Plummer and Boothby (140) found that 10 drops of
iodine well diluted with water is the average optimal dose
in moderately severe oases.

In a mental or gastric crisis,

they increased the dosage to 10 drops 3 or 4 times a day
for a few days and then once again decreased the dosage.
If it was impossible to give this orally due to vomiting,
they observed that it could be given per rectum with
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satisfactory results.

Plummer (180) also suggested the use
\

of 10 drops of Lugol's for 10 days post-operatively because
''the patient is short of iodine and dies for lack of it''.
Thompson, et al, (175, 176, 180) in Boston determined that the daily administration of about 6 milligrams of
iodine in the form of compound solution gives a maximum reduction in basal metabolic rate; 3 milligrams give s about 1/2
the reduction; and i 1/2 milligrams gives approximately 1/3
of the reduction of basal rate.

They definitely proved in

their series of cases that a small dose often interferes with
the action of a larger dose given at a later date.

They also

noted that the amount of iodine necessary to produce maximum
reduction in the basal metabolic rate varied with the weight
of the thyroid gland.

Thus it would appear that the percent-

age approach to the normal level, the daily dose of iodine
within the limits of .75 and 6 milligrams and the amount of
iodine avail~ble for the storage of colloid on doses with
these limits are roughly proportional.
Thompson, et al, (176) in 1930, observed that the
dose that wi ll give the maximum effect varies in the same
patient from time to time as does the response to the same
dose due to spontaneous variation in the disease.

(This

last variable may be due to an increase or decrease in the
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patient's activity.)

They noted that the speed of decrease

of basal rate was not affected by the size of the dose as
long as it was sufficient to give the maximum effect.

They

state that one drop of Lugol's solution contains 6 milligrams
of iodine and this dosage is satisfactory; i.e. one drop each
day is adequate dosage.
Clute (21) in a series of severe cases had excellent
results by giving a high dosage for the first few days.

He

gave 60 to 100 minims of Lugol's solution (3 to 6 cubic centimeters) in the first 2~ hours.
Goetsch (58) noted that intravenous sodium iodide
5 to 10 grains each day for 5 to 10 days gave a rapid effect
and was effective in the control of gastrointestinal crises.
It controlled the acute symptoms in a few days and even gave
a response in patients previously iodinized.
Non-operative treatment with iodine has been described in the li~erature, but the results are uniformly unsuccessful.

Cole (24) states that a safe and efficient dosage is 5

to 10 minims of Lugol's 3 times a day.

This can be continued

in most cases for the first few weeks of treatment, and thereafter 5 minims can be continued safely and with benefit for
6 months in most patients.
Dennig (39) believes that it is best to give this
type of treatment in series; i.e. give the iodine for 8 to 14
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days and then stop the dosage for 3 to 5 days.

He states

that the optimal dosage lies between 50 and 200 milligrams.
Eowever, he is free to admit that a complete cure is almost
never obtained.
Where there is an obvious physical or psychological
irritant factor which can be removed, Goadby (57) thinks that
this form of therapy has definite merit.

He believes that

Lugol's solution in dosages of 5 minims 3 times a day plus
rest and removal of the irritant factor will usually result
in a complete cure.
Plummer (139) originally utilized iodine postoperatively and Crile (28) in 1938 still used 1 cubic centimeter 3 times a day orally or rectally for the first 3 days
post-operatively.

This maintains the effects of the pre -

operative iodine and in 3 days the peak of the thyroid reaction has passed and the iodine dosage can be stopped.
He also states that if severe post -operative reactions develop, Lugol's solution up to 50 minims can be given intravenously

in 10% glucose with excellent results.
The chemical state or the route of entrance into

the body have no effect upon the action of iodine.

Cohn (23)

observed that free iodine, when introduced into the gastrointestinal tract was converted into iodide ·.

Since this is

true, the administration of potassium iodide orally, or
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Ethyl iodide via the lungs should be of the same value as
Lugol's solution.

Lerman and Means (90) observed that Ethyl

iodide 2 to 4 grams or potassium iodide :J/10 to 2/10 grams
were as effective as Lugol's solution.

Plummer and Boothby

(140) used Liquor iodi compositus (Lugol's solution) because
it provided a "lar ge amount of iodine loosely combined with
po.t assium11 ; assuming that more iodine wou ld then be present
for absorption.

.

Cohn's studies do not bear this out and

Lerman and Means have also refuted it.
From t h is discussion, it is obvious that there is
wi de variation in dosage, etc., but the diffe rence between the
dose of iodine giving full benefit and the toxic dose is so
great, that one need never worry about toxicity.

However ,

when the maximum effect can be obtained with the minimum
effective dosage, it is foolish to give excessive amounts.
Treatment with iodine is an art demanding intuition and experience; without these two assets, definite harm

may result.

However, in the hands of an experienced practi -

tioner, who knows the limitation of the treatment it is very
effective •
The classification presented below is a compilation of the reviewed literature.
1.

Cases treated with iodine in relation to a surgical
procedure .
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2.

a.

Pre-operative therapy

b.

Recurrent hyperthyroidism

c.

Post-operative therapy

Cases treated by a purely medical regime.
a.

Mild cases when there is an obvious physical or
psych ological irritant factor that can be removed.

b.

Mild cases at puberty
Cases of thyrotoxioosis treated pre-operatively

constitute the majority of patients treated with iodine.
Crile (28) states that t his therapy is carr i ed out to establi,s h a. lower plateau of activity, and when the basal metabolic
rate and heart rate curves level out, it is time t o operate.
Th is must be chec ked carefully, for it must be remembered
t hat the action of iodine is only temporary and merely holds
in abeyance a portion of the symptoms for a time.
is the optimum time for surgery.

This time

Boothby (12) states that

when iodine is used in correlation with surgery, it decreases
the number of operations necessary, decreases the mortality
and post-operative residuals, decreases the number of recurrances, and increas~s the operability.

It also markedly de-

creases the number of post-operative crises which increased
the surgical mortality rate so markedly in the pre-iodine era.
Haines (66) in a review of 123 cases showed that
25.2% of oases (recurrent post-operative) had been controlled
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with iodine.

He did not assume that the effect was curative,

but only that the manifestations were controlled.

Jackson,

(77) Thompson, et al, (178) and Goadby (57) also demonstrated
that certain recurrent cases could be controlled by a medical
regime.
Crile (28) utilizes post-operative therapy with
iodine until the peak of the thyroid reaction has passed in
order to maintain the beneficial effects of the iodine given
pre-operatively.

Jackson (77) stresses the use of iodine

post -o peratively for 6 months or more in order to prevent
recurrent or persistent hyperthyroidism.
Goadby (57) notes that thyrotoxicosis is more
certainly cured by operation, but that it is a self limiting
disease so medical therapy has a definite place in certain
cases.

Mild oases in which there is some obvious irritant

factor which can be removed often react very favorably to a
brief medical regime of therapy and removal of the irritant
factor.

Also. mild cases at puberty can be well controlled

by a low dosage of iodine until they become more mature at
which time, they usually recover by themselves.
Thompson and Thompson (181) state that during
prolonged therapy with iodine, the basal rate will usually
rise gradually back to its original position .

However ,

these iodine refractory patients, if kept off of the drug,
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are again responsive to it in approximately 4 weeks.
was also observed by Graham. ( 62)

This

The rate at which patients

become refractory to iodine is not standard, and certainly no
causative factors have been determined.

However , luckily for

the patient, there seems to be a complete recovery from ref'ractorine ss after iodine is omitted for the basal rate drops
just as mar kedly during the second course of' treatment as it
did in the first.
According to Graham, ( 62) ''Clinical experience has
demonstrated the utter futility of' further iodine therapy in
the already overiodinized patient".
A:n important axiom to remember is NEVER GIVE THIS

DRUG WITHOUT A DEFINITE OBJECTIVE .
It must be remembered that iodine therapy is not a
cure for thyrotoxioosis, but merely gives symptomatic improvement for a time.

In patients being prepared for operation

the optimum time must be chosen by careful observation of the
patient , for if the iodine therapy is continued beyond the
period of maximum effect, the basal rate steadily rises again.
There is a · great deal of controversy over refractoriness to iodine therapy.

Some writers believe that the re-

fractoriness is merely apparent and not real and that it is
due to therapy on the upswing of the cyclic course of' thyrotoxicosis. (10, 111, 115).

However, if thi~ were true,
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would there not be more refractory patients, fo r what patient
seeks the advice and therapy of a physician when he is improviug.

Also, there are very few "fast" patients among those

who have not been treated before.

It has also been noted

that a dose of iodine which in itself is too small to cause
an effect may cause refractoriness to larger doses, and that
the size of the dose seems to have little to do with the
development of refractoriness to iodine. (181).
In patients with

a

large toxic thyroid giving

pressure symptoms care must be taken for iodine therapy often
causes an increase in size of the gland and consequently
would give an increase in pressure symptomatology.
Iodine control o_f thyrotoxioosis is purely relative and not absolute so supreme confidence should not be
placed in it.
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•

RADIOTHERAPY •

The first .American reference to radiotherapy in
the treatment of thyrotoxicosis was made by Williams in
his book on _T_h_e_R_o_e_n_t__g__e_n_R_a..._y in Medic_i_!l._e_ and_§ur_g~~r~y ( 189).
Campbell reported i mprovement in a patient who had thyrotoxicosis and was treated for acne about the neck with
radiotherapy. _ This opened a new approach to the problem
of thyrotoxicosis and produced a number of reports.

In

1916, the whole field of treatment of thyrotoxicosis with
radiotherapy was reviewed by Pfahler and Zulick. (138).
They derided the haphazard way in which roentgenologists
had reported the cases treated, and the indefinite manner
in which the treatment had been handled.

However, from a

review of the literature they concluded that there was
definite value in the therapy and recommended that all
cases of hyperthyroidism s~ould be given at least one
roentgen treatment and then wait one month before operation.

Foll~ning this article roentgenologists made a

determined effort to correlate findings and technique and
as a direct consequence, the field was clarified and definitely outlined.
As a whole, in the articles that have been reviewed, reports from radiotherapists on the treatment of
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thyrotoxicosis with radiation have tended to be over enthusiastic, very technical, and often lacking in sufficient
olinioal details on the oases treated.
Remer0an~ Belden (148) recommend irradiation for
treatment of t hyrotoxicosis and gives the or der of improvement r as: , f irst, improvement in nervousness, then decrease
in heart rate, with exophthalmos a nd goiter the last symptomatology to disappear.

The nervousness and decrease in

heart rate usually disappear after the second treatment,
and as they decrease, the dyspnea is decreased and the
choking sensation disappears.

Also, the tremor disappears .

and t here is an increase i n weight.

They observed that it

usually took 7 to 12 months to effect a cure.

They believe

that if there is no improvement in 4 treatments, surgery
should be r e sorted to .
In 1930, Pfahler and Vastine (137) reported on
the resu l t s of roent gen therapy in 400 cases in whioh 86%
of 235 cases were cured or markedly improv ed.

Of the

patiehts seen duri ng the first 3 months of the disease,
96~~ were cured.

They conclude that the earlier in the

course of the disease that therapy is instituted, the
better are the chances of complete recove ry.
In 1929, Grover, Christie , et al, (64) reported
the results of irradiation therapy in a series of 305
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oases as follows:

approximately 89% cured, 8% improved,

and 3% unimproved.
needed was 6.6.

The average number of treatments

Their criterion for "cure" was a disap-

pearance of signs and symptoms of thyroid intoxication
with a return to normal of the basal metabolic rate.
However , their "cure" did not necessarily imply a disappearance of some of the associated effects of the disease.
The factors that they noted as being contributory to
failure were overwhelming toxicity, seriou s cardiovascular
or other visceral changes and non-cooperation.

J. H. Harris (68) published a report of cases
treated at the University Hospital of Pennsylvania from
1926 to 1933.

He showed good res ults obtained in 69.9%.

He also demonstrated a. progressive improvement in yearly
per oent of go od results.

He noted that only 53% of the

toxic nodular group was helped .

He states that the best

prognosis can be given the patient whose major symptom is
nervousness, who has a small soft goiter, and who has been
ill for 6 months or less.

He also makes the statement that

all children with thyrotoxicosis should hav~ a course of
radiotherapy before surgery is considered.
Soley and Stone (165) reported in 1943 a series
of 43 patients treated with 58.1% cured, and 18.6% improved.
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Richter (151) concluded, after a review of the
literature, that the radiological treatment of thyrotoxicosis
has not been given adequate study.
50% failures are commonly admitted.

He states that 20 to
In his opinion only

very mild, early, adolescent cases and patients with associated lesions incompatible with reasonable life expectnncy may be advantageously treated by roentgenologists.
He brings up the very pertinent time factor in this form
of therapy.

He maintains that entirely too little prominence

is given in the literature to the time required for a cure.
In many cases this plays an important part in the organic
damage sustained.

Every day that passes with the patient

in a toxic state means that much more visceral strain.
There are some massive reports of oases in the
literature (119), but these are cases collected from
roentgenologists all over the country.

I hesitate to

attach much value to them for there can be no uniformity
of inter pretation of such terms as cures, improvements,
etc.; nor can the accuracy of observations be relied upon.
It is the general feeling among radiologists
that radiotherapy deserves a more prominent place in the
treatment of thyrotoxicosis. They state that clinical
•
results and permanence of this form of therapy compares
favorably with other forms of therapy •
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The method of action of irradiation on the
thyroid gland is not as yet definitely established.

In

a series of 291 cases operated on in the Mayo Clinic and
who had been previously treated with radiation, no gross
changes could be ascertained, and microscopically, Broders
(132) could not distinguish irradiated from non-irradiated
tissues.

On the basis of this wor~, it was assumed that

the beneficial effeots of irradiation were due to functional rather than organic changes.
The theory most commonly held by radiologists
is that advanced by Holzknecht some years ago. (75).
He believed that x-rays acted by inhibition or depression
of the growth and function of the cells and stated that
x-rays relieved hyperfunotion in the same ways as did
surgical removal.
Freid and Goldberg (48 ) found the normal thyroid
gland very resistant to irradiation.

Patients treated

for malignancies in the neck and larynx have received heavy
irradiation over the thyroid, yet rarely if ever is myxedema
produced.
Although, previous research had been done upon
the thyroids of animals in attempting to discover the
effect upon them by radiation, the first opportunity to
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study the effect upon humans came to Friedman ahd Blumgart.
(49).

Four of their cases were given large amounts of

radiation over the thyroid in an effort to eliminate thyroid
function in patients suffering from chronic cardiac conditions.
Doses 2 to 3 times the amount usually given to thyrotoxic
patients had no influence upon the basal rate.

Three months

later total ablation of the gland was done on 2 patients
and the pathological report was normal thyroid tissue.
Pfahler and Zulick (138) originally propounded
this theory; since the highly specialized epithelial cells
are the first to succumb to the action of x-rays, and the
more closely these cells approach the embryonal type the
more easily they degenerate; then it would seem that the
pathological histogenesis of the thyroid in thyrotoxicosis
would easily be controlled by radiotherapy.

However , as

has been stated earlier, the microscopic picture after irradiation is definitely not one showing destruction .

There-

fore, it seems that the mode of action is one of inhibition
rat her than destruction.
The technique of radiotherapy in thyroid diseases
varies to a considerable degree in different clinics, but
the basic principles are approximately the same.

This

applies not only to the voltage used, but also to filtration,
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focal skin distance, size of ports, number of ports,
intensity of radiation, time interval between treatments,
dosage per course, number of courses, etc.

Rather than

attempt to evaluate critically, the individual therapeutic
regimes, I will present four methods of therapy which,
though varying in technique, have given approximately the
same results, and in my opinion represent a good cross
section of this field of therapy.
The routine procedure of J. H. Harris (68) in
t he treatment of thyrotoxic patients consists of first a
careful examination of the patient, including a basal
metabolic rate and com9lete physical, and a roent genograrn
of the che st to exclude a latent tuberc ulosis or a substernal thyroid.

Most frequently he gives his patients

3 series of treatments of 3 weeks, follow i ng which a
basal rate and complete chec k up are given.

The roentgen-

ray factors are a 155 kilovolt peak ; 5 milliamperes; with
.25 mm. of copp er plus 1 mm. aluminum filtration and 30
centimetere distance.

The portal used is 12 by 15 centi-

meters and covers the anterior t hyroid area.
is protected from direct radiation.

The larynx

The treatments are

conti nued until the basal rate is between O and plus 10.
As the rate subs i des an~ approaches normal, the readings
are made 3 or 4 weeks after each treatment.
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He employs a second technique at times in those
oases in which the low voltage has been ineffective.

In

this he uses a 165 kv peak; 15 ma; .5 Cu plus 1 Al filtration; and 50 cm. distance.
the lower voltage.

The same portal is used as in

200r, measured in air, is given every

other day for 3 days, and 600r constitutes a series.

A

basal rate is taken in one month and further therapy depends
upon the results obtained.

It appears that the change in

wave length has a beneficial effe~t upon a certain number
of cases.
Barrow (6) used 100 to 125 kv with 3 to 4 mm.
aluminum filter, and states that 250r can be given weekly
for 6 to 8 weeks without danger of skin reaction; or with
200 kv, 3/4 nun. Cu filter, 500r may be given weekly for
4 to 6 weeks with only slight skin reaction.

By means of

this more intensive therapy, or by means of the usual dosage
more frequently applied, the toxicity can be overcome in
6 to 8 weeks.

Pfahler (134) states that he routinely uses 130
kvs, 5 ma, at 25 to 30 cm.

He uses the equivalent of 6

mrl.llimeters of aluminum filtration.

The cerviqal region is

divided into 4 fields, approximately 5 by 15 centimeters,
2 of which are anterior and 2 are posterolateral.
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These

4 areas make up one series and they are usually given in
1 day, repeating this series in 3 weeks, then in 4 weeks,
increasing the interval according to the improvement obtained.

In mildly toxic oases, he gives an initial 50% skin

erythema dose through each of the 4 portals.· Then this is
repeated in the usual sequence.

In the more severe cases,

it is better to begin with smaller doses, not exceeding
40% at the first series.

This may be increased in the sub-

sequent series.
The regime of Freid and Goldber g (48 ) consists
of 200 kv, 50 om., 30 ma, .5 mm. Ag plus 1 mm. Al.

Two

fields are used in most cases, a right and l e ft lateral
port the size of the lobe, cross firing the gland.
per treatment is 150 to 250r per port.

Dosage

Usually one lobe

is exposed per sitting, the opposite being exposed 3 or 4
days later.

Exposures are given weekly until each port

receives lOOOr.

However, if the patient recoversprior to

this time, treatment is discontinued.

If necessary, a

second course is given in 3 months.
I have possibly ma.de it seem that these regimes
were rigid and invariable, wh ile actually this is not the
case.

Each technique varies with the individual case, the

duration, severity, age, eta.
Grover, et al, (64, 65) stress the extreme
importance of the general management of the patients in44

eluding rest, diet, etc.
tion of risks.

They also stress careful selec-

One other thing that cannot be stressed

too much is the accurate calibration of the machine in
roentgens.

It is only in this manner that an accurate

knowledge of dosage can be recorded and by this method
most of the complications can be prevented.
Application of t his form of therapy varies with
the clinician.
(151)

Extreme conservatists, such as Richter,

use radiotherapy only in mild, early, adolescent

oases, and cases with associated lesions not compatible
with life.
Soley and Stone, (165) a little less conservative,
utilize this form of therapy in all patients who have a
moderately severe thyrotoxioosis without complications,
except those with nodular toxio goiters.

They feel that

these should have the benefit of surgical removal with
histological section.

J. H. Harris (68) gives t h is classification of
cases to which this form of therapy is applicable .
1.

Post-operative recurrences without selection.

2.

Patients in whom it is felt that roentGen irradiation offers a reasonable change of cure
without the necessity of operation.
a.

Those with mild to moderate degrees of
hyperthyroidism in whom the predominant
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sympton is nervousness, and in whom there·
are no evidences of visceral damage.
b,

Those with little or no lows of weight.

c.

Those with s l ight to moderate thyroid enlargement and in whom the go_iter is not
hard and nodular .

d.

All children with toxic symptoms except
those with toxic nodular goiters,

e,

Patients wi~h a poor operative risk,

f,

Patients refusing surgery,

The roentgenologists emphasize the fact that
the primary mortality is nil, and that the pre- and postoperative morbidity are el~minated,

There is no fear of

. operation, no economic interruption, and no pain or shock.
However . efficient this form of therapy is, it
should never be used with the threat of thyroid crises or
in the presence of pressure symptoms.
It is the feeling of most roentgenologists that
the results of this form of therapy in toxic nodular goiter
is so markedly less effective than surgery that treatment
of it should be relegated to the surgeons. (165, 68, 69, 151).
As with any form of therapy, there are dis-

advantages in the radiation treatment of hyperthyroidism.
The treatment extends over some little ti~e and there is
always the definite possibility that very serious viceral
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changes will take place before the beneficial results are
manifest.

This possibility can be' prevented by a caneful

s e lection of patients and by a careful observation and
check of the status of the ,disease while treatment is being
given.
In the early literature before t he dosage and the
amount of filtration were standardized, myxedema was reported commonly.

Now, however, Harris (68 ) has shown con-

clusively that adequate doses of irradiation may be safely
applied to the thyroid without producing e i ther serious
skin changes, or hypofunction of the normal . thyroid gland.
Th is was also observed by Pemberton (132), while Pfahler
(136) does not report any cases of myxedema following his
series of 503 cases treated by radiotherapy~
A temporary exacerbation of symptomatolo~y can
be expected for 24 to 72 hours after the first few treatments, but t his reaction is not serious and ordinarily subsides with rest and sedation. (6 8 ).

However, Giles (54)

states that in his experience, he has never seen any postradiation exacerbation.
Harris (6 8 ) notes in an occasional patient, that
there is a slight to mild skin reaction in the area treated.
This is never more than a first degree reaction and soon
disappears.

In the earlier periods of treatment, an oc-

casional case of telangiectasis was seen as a late result
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of therapy.

Giles (54) reiterates these statements but

notes that in the hands of an experienced radiotherapist
these conditions are rare.
In the earlier treatments, tracheitis, laryngitis,
and esophagitis were observed quite often.

But with the

advent of increased filtration, dec reased ~oltage, and
protective shielding there was a marked decrease in this
invo l:vement • ( 48, 16 5) •
Statistics indicate that recurrences are not
more prevalent than after surgery.

Holznecht (75) places

failure at approximately lo%, while Manville ( 119) in a
recently collected series of 10,541 oases from 75 sources
reports 12% failures. ·
There has been considerable discussion concerning the difficulty of post irradiation surgery,

Roent-

genologists have attempted to disprove the surgeons'
claims that radiotherapy produces dense adhesions.
Pemberton (132) reports on a series of 4,061 patients with
exophthalmic goiter who were operated on in the Mayo Clinic.
Of this number 291 or 5% had had previous irradiation.
Gross changes could not be demonstrated, and Broders could
not distinguish radiated from irradiated tissue.

In spite

of this proof surgeons look with extreme pessimism on any
post irradiation surgery on the thyroid.
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THERAPY WITH THIOURACIL.

In 1941, Mackenzie, Mackenzie , and McColl~(lOO)
while observing the effects of the feeding of •various
diets,to which sulfaguanidine had been added,to rats,
noticed that the thyroid became hyperemic and enlarged
to several times the size of those of the control animals
which received the same di ets without sulfaguanidine.
Histologically, the epithelium of the hypertrophied
thyroids was columnar in type with papillary overgrowth,
and there was an associated quantitative depletion of the
intrafollicular colloid.

They also noted that this effect

was not altered by the giving of iodine, but that it was
abolished by the use of thyroxin.

They became interested

in this phenomenon and further investigation by these
same workers showed that an enlargement of the thyroid
could be produced by other compounds of the sulfonamide
series and by thiourea.
While making studies on the graying of hair
produced by the ingestion of phenylthiocarbamide (phenylthiourea), Richter and Clisby (152) also described the
development of thyroid hyperplasia.
In a more extensive disquisition, the Maokenzies,
(99) reporting the results of their studies of a series of
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sulfonamides and thioureas, stated that in addition to the
anatomical changes produced in the thyroid as previously
noted, the basal metabolic rate of the treated animals was
markedly reduced.

"Thyroidectomy cells" were obserTed in

the - pituitary ; and hypophysectomy prevented the characteristic
hyperplastic changes in the thyroid which had been found to
follow the feeding of sulfaguanidine to normal animals.
Similar observations were ¢ade by Astwood (2) who,
as a result of testing more than 100 different chemical
compounds with regard to their relative effectiveness in
inhibiting the functional activity of the thyroid glands
of rats, concluded that 2-thiouracil was not only the most
potent, in this respect, but the least toxic.

Most of the

derivatives of thiourea showed some activity, but there was
wide variability in toxicity.
In the light of such oonvinc ing experimental data,
clinical ap plication was inevitable.

Astwood introduced a

new therapeutic principle when he reported on 3 oases with
hyperthyroidism who had been treated with thiourea and
thiouracil, (1) administered orally.

The results were

favorable as judged by the relief of symptoms, and due to
this stimulus a great amount of literature on experimental
data and clinical application has been published .

Howeve r,

questions relating to the permanency of the improvement and
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particularly the end results of this type of chemotherapy
await decision.

Whatever the final decision is , the mortality

rate of .5% must be kept in mind.
Williams, Kay and Jansdorf, (196) in 1941, conducted extensive experiments on the absorption, rate and excretion of thiouracil.

They observed that in humans, the ab-

sorption of the drug from the gastrointestional tract is
very rapid, and all of .it is absorbed or destroyed before
the jejunum is reached.

It was found that approximately

8o% was gone from the gastro -intesti nal tract in 2 hours .
In rate it was observed that 25% was des.troyed in the

in-·

testine and stomach, while in hUI!lans it was estimated, but
not conclusively proven, that 15% was destroyed.

They found

that after oral administration, the highest blood level
comes in the first hour, and usually in the first 15 minutes.
Under a regular dosage, the blood level becomes relatively
constant in 24 to 48 hours.
Following oral administration, the urinary excretion begins in 30 minutes and has its maximum in 2 hours
and then decreases.

Under regular dosage, the excretion in

the urine becomes relatively constant in 24 to 48 hours .
After discontinuance of a short course of therapy, the drug
is gone from the blood in 48 hours; however, the longer it
has been administered, the longer it is present in the ilood
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stream and consequently in the urinary excretions.

There

is, on the average, about 33% of the total ingested amount
excreted ih the urine.

There is no elimination of thiouracil
,

This is due to the fact that the drug is

in the faeces.

absorbed or d~stroyed high in the gastrointestinal tract.
A question was raised as to the destruction of the drug

the colon bacilli, but this was disproven.

by

However, staphylo-

oooci caused the destruction of 35% and streptococci the
destruction of about 50% of the drug in experiments conducted in vitro.

The excreted substance is found in the urine

in the form of organic sulfur compounds.

However, the stand-

ard test for these compounds is the Grote reagent, and it is
possible that some of the sulfur compounds do not give the
color reaction.

This would destroy the validity of the

quantitative test.
Blood and Lewis (11) observed that the greater
part of the drug appears to be excreted as suoh in the urine.
After oral or parenteral administration of thiourea to
rabbits, there was no evidence from the study of the partition of the urinary sulfur that the su lfur portion of the
molecule was oxidized to sulfate.
Many interesting observations have been made concerning the distribution of thiouracil.

A series of tests

were run after regular dosage for 3 days which should have
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allowed the blood level to stabilize.
level was 2.5 mgs% in nearly all.

The average blood

This blood level was

apnroximated in most oases ih spite of a wide iva.riance in
dosage.

The greatest concentration of the drug was found

in the pituitary, adrenals, bone marrow, and thyroid.

The

kidneys, spleen, and pancreas also showed large amounts.
Muscle, liver, and testis showed ohl y small amounts .

In

general, the concentration in the tissues was many times
as great as it was in the blood.

However, these tests

were run ante mortem and post mortem in patients with a
hopeless prognosis and patients in extremis with correspondingly low basal metabolic rate, and t h is must be taken into
consideration, for in patient~ with a higher basal metabolic
rate, the liver and muscle showed a somewhat higher concentration.

The oerebrospinal fluid, edema and pericardial

fluids have less concentration of the drug than the blood.
Ascitic and pleural fluids have a concentration about equal
to the blood while milk has a.bout 3 times as much. ( 196) .
It was observed in certain patients with nephritis
and i mpaiied excretion that even though the same dosage of
thiouracil was given and very little was excreted, in the
urine, the blood level stayed the same as in the normal case.
This would seem to indicate that the drug was broken down
in the body tissues.

Attention naturally turned to the liver,
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but in patients with severe liver disease no abnormal rise
in blood level was found.

In a series of tests on the destruc-

tion of the drug by tissue slices it was observed that the
pituitary was the most active, the n the thyroid, adrenal,
with the muscle and pancreas the le a st active. (196).
Williams, (190) by experimentation, showed that
whe n the blood level was hi gh, the amount of destruction of
the drug increases and vice versa.

Consequently, to avoid

waste, give the lowest possible effective dose.
It has been estimated, but not conclusively proven,
that 15% of thiouracil is destroyed by the gastrointestinal
tract, 53% excreted, and the rest is destroyed by the tissues.
The mode of action of thiouracil appears to be an
inter1·1:1renc1:i with the enzymatic synthesis of thyroxin.

The

exact point of the interruption of the cycle is · still not
known, but it is definitely established that the thyroid is
rendered incapable of utili~ing iodine.

The resultant thyroid

insufficiency leads via anterior pituitary stimulation to an
ineffectual hyperplasia of thyroid cells.

The peripheral

action of administered thyroxin remains unimpaired.
It has now been established

that the endocrine

function of the thyroid gland can be ihhibited
of t h iouracil.

by the action

Astwood (2) observed that t h iouracil inhibits

the formation of new t hyroxin without i mpairing the action
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of that already formed.

So in Graves disease, the response

is fast, but in large nodular goiters or in cases of iodine
treated patients , and in normal persons , the reaction is slow.
He reasons that there is a partial failure of thyroxin synthesis rather than a total inhibition.

The striking increase

in the size of the thyroid in the original experimemtation
on rats was probably due to a total inhibition due to the
heavy dosage.
Campbell, Landgrebe, and Morgan (17) have postulated this theory; iodine is usually oxidized by enzymes to
iodides and it is then available for combination with tyrosine to form diiodotyrosine.

However , thiouracil has a

peculiar affinity fo r iodine, so if present a ll of the time
in the thyroid, it will at once bind any iodine liberated
to form formidine disulphide hidriodine instead of allowing
the fornation of diiodotyrosine.
Westerfe ld and Lowe ( 187) believe that the oxidative coupling of two molecules of diiodotyrosine may be produced under the stimulation of peroxidase.

There is a definite

possibility that thiouracil may decrease or inhibit pe roxidase.
There is a rapid loss in iodine from the thyroid
gland following initiation of thiouracil treatment.

It is

a regular and even process related to the normal rate of
secretion of the thyroid hormone .
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This decrease closely

follows the loss of colloid .

It has also been noted that

the thyroid hyperplasia is not markedly affected by iodine
in the diet, but that the effect is abolished by thyroxin.
Astwood (2) proved that these compounds related to
sulfanila.mide and thiourea had no influence upon the thyroid
in the absence of the . hypophysis and have no inhibitory
action upon the oalorigenic action of artificially administer ed thyroid hormone.
Keston , et al~ (82) administered radioactive
iodine to young and adult normal rats and thiourea fed rats .
Analysis of the thyroid glands of the thiourea fed rats 48
hours after the injection of the iodine revealed no appreciable amounts of radioactive iodine in any form whereas
thyroid glands from normal rats conta~ned considerable
amounts of radioactive iodine chiefly in organic combination.
These findings were duplicated by Franklin, et al, (45) and
Rawson. (145).

This wou ld seem to indicate that the drug

prevented absorption from the blood stream.
Though the site of action of thiouracil is not
definitely known, it is definitely know that in some manner
it prevents the formation of thyroxin.

It does not prevent

the peripheral action of the thyroxin .

The failure or de-

crease in the secretion of thyroxin results in a stimulus
to the pituitary and the resulting increase in the secretion
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of the thyrotropic hormone results in the hyperplasia of the
gland .

Ablation of the pituitary gland prevents changes in

the thyroid, but it does not prevent a fall in basal metaboiic
rate.
Astwood (1) observed that the la.tent period of the
drug is very short and following this short period, the rate
drops rapidly for two weeks and then more slowly thereafter.
He noted that irritability, apprehension, and feeling of
tension improved within a few days, while improvement of
palpitation, thermophilia, and sweating followed the drop
of the basal metabolic rate.

Diarrhea, when present was

slower to respond, while muscle weakness was the last of
the symptomatology to disappear.

More increase in the. size

of the gland was expected due to the marked goitrogenic
action seen in the initial experimentation, but this did
not materialize , probably, as has been mentioned before,
due to the fact that there was a partial failure of thyroxin
synthesis rather than a total inhibition.
The response to therapy is striking.

Within one

week the patient notices improvement, but changes are more
marked during the second, third, and fourt h weeks.
6 weeks of therapy few symptoms occur.

After

The basal metabolic

rate returns to normal in 2 to ~7 weeks, usually 5. (191).
It was noted by Reveno (150) that in diffuse toxic
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goiters, there was subjective improvement in 3 to 4 weeks,
while in adenomatous goiters, the effect comes in approximately 9 weeks.

Both of these figures are definitely prolonged

by the use of iodine before this therapy was attempted.
The creatinuria, which is always associated with
hyperthyroidism, is decreased by therapy with thiouracil,
but it still stays slightly above normal.

It has also been

demonstrated that the nitrogen, phosphorus, and calcium .
balances which are negative in thyrotoxicosis became progressively more positive.
cretion in the stool.

There is a decreased calcium ex-

There is an increase in the blood

cholesterol and a decrease in the protein bound iodine of
the plasma which are respectively low and high in th¥rotoxicosis. (161).
The drug results in thyroid hyperplasia , and when
disoont,inued, it would seem that it would cause an exacerabtion of the symptoms.

However, some cases remain

in re-

mission so certain changes must take plaoe under the influence
of thiouracil in the pituitary or in the thyroid or other
portions of the bodywhioh interfere with the manufacture of
the hormones or the capacity of the end organs to respond.
Williams (192) has noted that there is variation
in the response of the size of the gland ; some it doesn't
change, others get firmer and larger, others get softer and
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,

smaller.

Even though it may cause an initial enlargement,

for the most part a reduction in size occurs after prolonged therapy.
Thiouracil gives a gradual controlled suppression
of thyroid hyperactivity with great ease of reversability.
Though an improvement of subjective symptoms is difficult
to judge quantitatively, a sense of well being has been seen
3 days afte~ the initiation of therapy and is usually seen
by 7 days.

In diffuse goiters there is subjective improve-

ment in 3 to 4 weeks while in adenomatous goiter the effect
usually is delayed considerably, but the reaction to the
therapy is still satisfactory.
Every doctor that has used this drug has individual
variations in dosage; Williams' regime (192) seems to represent a composite view of the literature.

He uses an in-

itial dosage of .4 to .6 grams daily; after 2 weeks this is
decreased to .3 to .5 grams; a.fter a normal basal rate is
attained, .2 to .3 grams is used.

After a total of about 2

months of . thera py , only .1 gram is necessary usually.

It

is very important to choose the optimum dosage since excessive amounts of thiouracil seem to increase the toxic
action, may increase the size of the goiter ma r kedly, and
also increase malignant exophthalmos.

Roughly speaking,

there is a necessity for about l day of treatment for each
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increase of one point of basal metabolic rate.

In view of

the rapid absorption and excretion of single doses of
thiouracil, administration should be arranged so that the
absorption is distributed as evenly as possible over the
24- hour period.

With smaller doses given more often a

higher blood concentration is maintained and less of the
drug is excreted.
Reveno (15_0 ) noted that i n patients previously
under therapy with iodine, there is often an initial rise
in basal metabolic rate with thiouracil due to the release
from the influence of iodine and the delay in the onset of
action of thiouracil,

Williams and Clute (194) state that

there will be no exacerbation of toxicity after the initiation of therapy post-iodine if the iodine dosage is gradually decreased in the first 2 weeks of therapy in order to
allow for the maximum effect of the thiouracil.
As correlated treatment Williams (192) gives dessicated thyroid 32 to 92 milligrams a day.

This decreases

the size of the gland and also decreases the tendency to
exacerbation of malignant exophthalmos.

The dessicated

thyroid decreases the amount of stimulation to the anterior
pituitary .

This decreases the amount of thyrotropin secret-

ed, and the thyrotropin is the etiological factor in the
production of malignant exophthalmos, and increase ih thy60

roid hyperplasia (42).

Williams (194) also states that

200 roent~ens of radiotherapy each week will serve to decrease the size of the gland.
In a discussion of permanent medical treatment
with thiouracil, Paschkis (130) cautions a gainst prolonged
treatment with hi gh dosage which may lead to myxedema, and
against too rapid decrease in dosage wh ich may bring about
recurrence.

It is necessary to use the process of elimination

to establish the maintenance dose.
Lahey (88) has a very satisfactory preoperative
regime that brings the patient to the operating table in the
best possible condition wit h the thyroid gland in the condition best suited for operation.

He utilized thiouracil .6

grams daily until the basal metabolic rate is substantially
reduced and then as correllary treatment uses 30 drops of
Lugol's solution daily for 2 weeks to involute the gland.
The associated iodine t herapy decreases the size of the gland
or, at le ast, prevents further enlargement.

It decreases

the friability and vascularity, and the bleeding is then controllable.

However, care must be taken in this combination

pre-operatively for it may counteract the action of the
t h iouracil alone by storage of colloid.
Reveno (150) states that complete remissions can
be gotten, but that relapses are common.

Therefore, it is

best to determine the minimal maintenance dose and continue
it indefinitely.
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This chart r epr esents a t ypical response of basal
metabolic rate under therapy with thiouracil.

The therapy

consisted of .2 gram t.i.d. for 6 wks; .1 gram t-.i.d. for 4
wks; and • 1 gram each day as maintenance. ( 191).
After treatment, the enlarged thyroids are vascular,
the cells are tall and columnar, and there are numerous papillary projections into the acini.

The colloid is greatly de-

creased in amount and is very pale and there is a very low
iodine content to the colloid that did remain .

In many

cases, the acini are collapsed and appear merely as a mass
of cells.

The size of the gland depends upon the resultant

of the hyperplasia and t he decrease in the amount of colloid.
( 192).
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The failure or decrease in the secretion of thyroxin results in a stimulus to the pituitary.

The pituitary

shows changes like those following thyroidectomy; i.e., degranulation of cells, decrease in the number of acidophils,
vacuolation and increase in the number of and size of the
basophils, and slight increase in the interstitial cells .•
It would be difficul-t to discuss at any length
the clinical application of thiouracil therapy with all its
ramifications.
to.

Therefore, ·the following outline is resorted

It is a composite of all the discussions on therapeutic

application of thiouracil.
A•

CASES PREPARED FOR SURGERY.

l.

Patients with thyrotoxicosis who have a history
of a large colloid goiter before the advent of
toxicity, and whose goiter is now giving pressure
symptoms.

2.

Patients with toxic nodular goiter.

3.

Persons living at too great distance from medical
facilities to be checked weekly or bi-weekly.

4.

Patients lacking sufficient intelligance or perseverance to adhere to a prescribed routine without supervision.

This includes children and adol-

esce~ts unless the parents are cooperative.
5.

Those who prefer thyroidectomy rather than medical
management for economic reasons or because of the
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time factor.
The thyrotoxic action is much less severe in an
operation with preoperative medication with thiouracil than
with iodine.

A good anesthesia is obtained with cyclopropane.

The gland becomes friable and bleeds easily.

Postoperatively

the patient is calmer and has less cardiores piratory distress.
There is no thyroid storm because no thyroxin remains in the
gland.
B.

CASES CONTROLLED BY MEDICAL MANAGEMENT .

l.

Hyperthyroidism with diffuse hyperplasia.

2.

Toxic nodular goiter in elderly patients or in
those not considered to be good risks for operation
because of a concomitant disorder such as myocardial
failure, auricular fibrillation, hypertension, etc.

3.

Special cases where there is suspected a precipitating factor such as pregnancy, foci of infection, or
in young persons developing it as a result of emotional disturbance or other cause in whom the goiter
and toxic si gns are merely symptoms of a disease .

4.
C.

Recurrent post operative hyperthyroidism.

THE USE OF THIOURACIL IS EITHER NOT ADVISABLE OR IS
CONTRAINDICATED I N TEESE CASES .

1.

Patients who have on occasion exh ibited hypersensitivity or intolerance to the drug in the form of
rash, fever, or persistent fall in granulocytes .
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2.

Those who are not definitely thyrotoxic and in
whom a therapeutic response to iodine is necessary
to establish the diagnosis of hyperthyroidism.

3.

In many oases of cardiac or renal insufficiency
where a moderately high basal rate is found by
routine test and where there is no other evidence
of thyroitoxicosis.

In conditions such as this,

it is probably merely a compensatory mechanism.
Thiouracil has either no effect or brings about no
feeling of well being with a lowered basal rate.
4.

Instances of genuine thyrotoxicosis of the patient
cannot be observed at weekly intervals.

D.

THE USE OF THIOURACIL IS NOT CONTRAINDICATED IN THE
FOLLOWI NG CONDITIONS IF THE T1:i-YRorOXIC STATE REQUIRES

TREATMENT.
1.

Patients with a normally low white count, such as
3500, if the differential count is normal.

2.

Pregnancy - - Infants exposed to t h iouracil antenatally show no abnormality.

3.

Intervening infections, if the infection requires
therapy; there have been no evidence of drug incompatibilities.
Indications are that thiouracil is superior to

any other form of therapy utilized thus far in produoinJJ; and
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maintaining a remission of thyrotoxicosis.
The extended use of thiouracil will depend chiefly
upon whether its beneficial effects oan be obtained without
incurring undue risk as a result of its toxic action.

A

careful evaluation of this point is primary to any consideration of the problem as a whole .

The majority of the toxic

reactions that have been reported have involved the hemopoietic system.
One of Astwood's original patients (1) developed
a granulocytic angina, but this was under a dosage of 2 grams
a day.

This condition was also observed by others (97), but

in spite of their alarming symptoms, their recovery was complete upon cessation of the drug and supportive therapy;
pentnucleotide and crude liver extract.

It was not followed

by any detectable disturbance in the bone marrow activity
or in general health • .
Leultopenie. and relative lymphocytosis were noted
by several writers.

McGavick, et al, (97) noted it in 3

of their own patients, while it was also mentioned by
Gabrilove and Kert (51) and Palmer (129) in 3 more cases.
In 3 of these patients the reaction stopped without cessation of therapy while in the other 3, the treatment was
stopped and the blood picture returned to normal at once.
Wi lliams and Bissell (193) observed leukopenia and granule
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penia in other patients , but the incidence seemingly was no
higher than in the untreated thyrotoxic patients.

Moor~,

et al, (125) had 2 leukopenias in 52 patients treated with
t hiouracil, but the leukocyte count never dropped below 2500
of which at least 30% were polymorphonuclear cells.
Fever was the chief toxic manifestation in several
patients. (1, 51, 97) .

This reaction usually appeared early

in the regime of therapy with thiouracil and this fluctuant
fever, in association with urticarial skin rashes, leads to
the conclusion that such reactions are probably more in the
nature of a true sensitivity than the end result of a
cumulative toxic reaction. ·
Williams and Bissell (193) saw mild reaction in
3 of 9 patients treated.

In 2 of these slight pitting edema

with elevation of the serum chloride and decrease in the
carbon dioxide combining power occurred.

In the t h ird

patient, they noted swelling and tenderness of subma~illary
lymphnodes.

All these reactions disappeared without dis-

continuing therapy of 1.2 grams of thiouracil daily.

Williams

and Clute (194) in a later series of 72 patients observed
that 6 of these developed swelling of the legs not associated with any demonstrable pathology, but it was demonstrated
here that thiouracil in certain dosages may cause retBntion
of sodium, chloride, and water.
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In all of these patients ,

the edema disappeared without discontinuing t he therapy.
In this same series of 72 cases, 4 patients developed a morbilliform rash with severe pruritus, but this disappeared in s pite of continued treatment.
developed a mild urticaria.

Three other patients

This urticarial outbrea~ was

also observed in 2 patients by Gabrilove and Kart, (52) and
Sloan and Shorr. (161).
From the above, it can be seen that some form of
toxic reaction was observed in approximately lo% of the cases
reviewed (approximately 200).
but several were severely ill.

No fatal cases were discussed,
Astwood's contention (1)

that reactions will rarely be seen if large doses are avoided,
particularly for a ny length of time, seems to be well borne
out by these experiences.
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CONCLUSIONS.

l.

Psychotherapy is an important factor in the treat-

ment of thyrotoxicosis.

It cannot cure the disease, but

the process of mental adjustment is the foundation upon
which the efficacy of other measures depends.
2.

A concentrated diet, high in calories and carbo-

hydrate, should be given the patient.

Vitamin therapy,

especially A, B, and C, should not be neglected in longstanding oases.
3.

Hormonal therapy is still in too embryonal a form

to be considered seriously.
4.

In patients with thyrotoxicosis, thiouracil, when

administered in proper doses, will cause a drop in basal
metabolic rate to within normal limits and maintain it there
indefinitely.
5.

Toxic reactions have been consistently noted in

therapy with thiouracil, but a large number of these are
due to excessive dosage.

In cases in which these reactions

cannot be controlled, other measures must be considered.
6.

Cases which cannot be carefully supervised, and

consequently cannot safely be exposed to a prolonged exposure to thiouracil, can be best prepared for operation
by a regime of thiouracil to bring the basal metabolic rate
69

to normal.

During the lat~ 2 weeks of thiouracil therapy

preoperatively iodine should be given to involute the gland.
7.

In cases manifesting toxic reactions to thiouracil,

iodine therapy preoperatively is very satisfactory.

However,

care must be taken that the operation is performed at the
optimum time.
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